Email
Print
Needle Free Injection Systems Market - Forecast(2024 - 2030)
Needle Free Injection Systems Market Overview
The Needle Free Injection Systems Market size is estimated to reach $25.7 billion by 2026, growing at a CAGR of 14.2% during the forecast period 2021-2026. A needle-Free Injection System is a drug delivery system that makes use of Lorentz force, shock waves, pressure, or electrophoresis force to deliver drugs through the skin. They are seen as a superior alternative to the hypodermic needle as unlike syringe systems, Needle Free Injection Systems can be used multiple times without the risk of transmitting infections. Moreover, they help eliminate needlestick injuries and pain during drug delivery. An increase in the prevalence of needle stick injuries and fear of needles among the global population is anticipated to drive the market during the forecast period. However, the low levels of adoption and awareness in developing regions are anticipated to restrict growth opportunities for the Needle Free Injection Systems industry.
Report Coverage
The report: “Needle Free Injection Systems Market Forecast (2021-2026)”, by
Industry ARC, covers an in-depth analysis of the following segments of the Needle Free Injection Systems Market.
By Product Type:
Pre-Filled and Fillable Needle-Free Injectors.
By Technology: Jet-Based, Laser-Based, Vibration-Based, and Spring
Based Needle Free Injections.
By Site of Delivery: Intradermal, Intramuscular, and Subcutaneous
Injectors.
By Application: Pain Management, Insulin, Vaccine, Oncology, and
Others.
By Usability: Disposable and Reusable.
By Type: Powder injections, Liquid injections, and Depot or
Projectile Injection.
By End User: Research Laboratories, Hospitals and clinics,
Surgical Centers, Homecare Settings, Biotechnology, and Pharmaceutical Companies, and Others.
By Geography:
North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy,
Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South
Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America
(Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East
and Africa).
Key Takeaways
- Geographically, the North American Needle Free Injection Systems market accounted for the largest share in 2020 owing to an increase in the number of chronic and communicable diseases, high healthcare expenditure, and the presence of well-developed healthcare infrastructure.
- An increase in the cases of communicable diseases caused by the use of hypodermic needles is projected to drive the market during the forecast period. However, the lower cost of mass-producing hypodermic needle alternatives using injection molding techniques is anticipated to challenge market growth.
- Detailed analysis on the
Strength, Weaknesses, and Opportunities of the prominent players operating in the
market will be provided in the Needle
Free Injection Systems Report.
Needle Free Injection Systems Market Share, By Geography, 2020(%)
Needle Free Injection Systems Market Segment Analysis - By Technology
Based on Technology, the Needle Free Injection Systems Market is segmented into Jet Based, Laser-Based, Vibration-Based, and Spring Based Needle Free Injections. The Jet Based injection systems accounted for the largest share of the market in 2020 and is poised to dominate the market during the forecast period 2021-2026. This is attributed to factors such as lower time necessary for preparation and administration, ease of use and ergonomics, reduced instances of needle stick injuries, and lower risk of infection spread. The Laser based Needle Free Injection System is projected to exhibit rapid growth at a CAGR of 15.7% owing to its ability to accurately control the quantity and depth of drug delivery. Moreover, their high adoption levels in the aesthetic skin treatment procedures are another factor contributing to the growth.
Needle Free Injection Systems Market Segment Analysis - By End User
The Needle Free Injection Systems Market based on End User can be further segmented into Research Laboratories, Hospitals and clinics, Surgical Centers, Homecare Settings, Biotechnology and Pharmaceutical Companies, and Others. The Hospitals and Clinics segment accounted for the largest share of the market in 2020 owing to the high demand for drug delivery systems in hospitals and clinics caused by the large patient footfall. Hypodermic needles can only be used once and therefore after the drug is administered, they have to be disposed of. This is causing a massive rise in medical waste, which is increasing the spread of communicable diseases. These factors are causing hospitals and clinics to adopt needle-free injectors as they are more efficient, safer, and reduces wastage. The home care setting segment is anticipated to witness the fastest growth with a CAGR of 16.2% during the forecast period owing to the rapid surge in the diabetic population.
Needle Free Injection Systems Market Segment Analysis - By Geography
The Needle Free Injection Systems Market based on Geography can be segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. The North American segment is projected to dominate the Needle Free Injection Systems market during the forecast period 2021-2026 with a market share of 35% owing to the presence of highly developed healthcare infrastructure, high patient awareness levels, increasing cases of chronic illnesses, and high research and development in needle-free injection technology in the region. The Asia Pacific region is predicted to register the fastest growth owing to the increase in disposable income and growth in public healthcare funding in major emerging economies like China and India. The increase in the rate of adoption of needle-free injectors for vaccination purposes is another major factor for the rapid growth in the region during the forecast period.
Needle Free Injection Systems Market Drivers
Increase in Population Suffering from Diabetes is Projected to Drive Market Growth
According to the World Health Organization (WHO), there are more than 422 million patients suffering from diabetes worldwide and 1.6 million diabetes-related deaths occur worldwide each year. Furthermore, the low and middle-income countries are witnessing a more rapid rise in diabetes cases than the high-income regions. Many of these patients need to take insulin injections to manage their condition. For instance, of the 30 million people in the US with diabetes, more than 9.3 million or 31% need regular insulin injections. This is anticipated to drive the Needle-Free Injection Market as these devices provide a safer, more efficient, and less painful alternative for insulin delivery. Moreover, around 50 million people in the US suffer from Trypanophobia or the fear of needles. This can be overcome through the use of needle-free injection devices.
The Rise in Needle Stick Injuries is Anticipated to Boost Product Demand
According to Occupational Safety and Health Administration
(OSHA), there are between 600,000 and 800,000 needle stick injuries recorded in
the US each year. It is estimated that around 3.5 million needlestick injuries
occur worldwide annually. These injuries pose a huge risk for healthcare
workers as needle sticks can expose them to more than 20 different pathogens,
including Hepatitis B, Hepatitis C, and even HIV. Around 6% to 30% of all
Hepatitis B, 1.8% of Hepatitis C, and 0.3% of HIV infections are caused by
needle stick injuries. This is driving the demand for needle free injection
systems as they eliminate the risk of the spread of such pathogens and thereby,
improve the safety conditions of healthcare workers.
Needle Free Injection Systems Market Challenges
The Low Awareness of Needle Free Injection Systems is Anticipated to Hamper Market Growth
The low awareness levels of needle free injection systems in low and middle-income countries is predicted to hamper growth opportunities. This is attributed to the poor rules and regulations regarding medical waste management and low safety standards in these regions. For instance, according to a study by the National Journal of Community Medicine, around 23% of the observed healthcare providers in an Indian hospital left the needle on the top of the vial for an additional dose. The lack of safety standards and waste disposal regulations gives hospitals no incentive to invest in innovative technologies such as the needle-free injection system for improving safety and reducing waste generation.
Limitations Regarding Intravenous Drug Administration is Projected to Limit Growth Opportunities
Needle-Free Injections systems are unable to
deliver intravenous drugs. This is a major challenge as they are not able to
become an alternative for needles in this segment. Chemotherapy drugs such as doxorubicin,
vincristine, and cisplatin, antibiotics like vancomycin, meropenem, and
gentamicin, and antifungal drugs like micafungin and amphotericin can only be
administered intravenously. Moreover, pain relief medications such as morphine
and immunoglobulin medications (IVIG) cannot be administered through the skin.
This significantly limits the applications of needle free injection systems,
thereby reducing their demand.
Needle Free Injections systems
Market Industry Outlook:
Product launches, mergers and
acquisitions, joint ventures, and geographical expansions are key strategies
adopted by players in the Needle-Free
Injections systems Market. The top 10 companies in of the industry include:
- Medical International Technology (MIT)
- Injex Pharma AG
- Endo International PLC
- Antares Pharma
- PharmaJet
- National Medical Products Co Ltd
- Glide Pharmaceutical Technologies Limited
- Valeritas Inc
- Inovia Pharmaceuticals
- European Pharma Group
Partnerships/Product Launches:
- In August 2021, Zydus Cadila announced it received approval for its Needle-Free COVID-19 vaccine in India. Zydus will use a needle-free system manufactured by Pharma Jet to administer the vaccine doses.
- In October 2020, PharmaJet announced that its Stratis Needle-free Injection System will be used to deliver a vaccine against COVID-19 in a clinical trial in Australia.